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DI was managed with DDAVP 0.2 mg by mouth twice daily.  
Oncology was consulted who recommended chemotherapy 
(Cladarabin) as outpatient Currently she has completed treatment 
with Cladarabin with more than 33% shrinkage in tumor size and 
mass symptoms.   
 
 
 
 
 
 
OBJECTIVE 
 
To emphasize the importance of early suspicion and detection of CNS 
Langerhans Cell Histiocytosis (LCH) in a symptomatic patient with 
Diabetes Insipidus (DI) and discuss  the evolution,  progression and 
treatment of CNS LCH. 
INTRODUCTION 
 
LCH is a rare disease with an annual incidence of 3-5 cases per 
million. It is characterized by aberrant proliferation of specific 
dendritic (Langerhans) cells belonging to the monocyte-macrophage 
system. These cells can infiltrate virtually any organ without 
necessarily inducing dysfunction. LCH shows a particular predilection 
for involvement of the Hypothalamo–Pituitary Axis (HPA), leading to 
DI. The incidence in adults may be underestimated due to the fact that 
many cases likely  remain undiagnosed. 
 
                           CASE PRESENTATION  
 
A 53 year old post-menopausal female presented to her primary care 
physician with complaints of headache and blurry vision for 2-3 
months. MRI of the brain revealed a lobulated enhancing mass 
centered in the suprasellar location measuring 2.8 cm (AP) x 2.4 cm 
(Transverse) x 1.6 cm with hyper intensity on FLAIR (see fig 1). 
During this time frame the patient was diagnosed with 
hypothyroidism. A review of systems revealed that the patient had 
polyuria, compensated with polydipsia for a few years preceding the 
headache. MRI guided right fronto-temporal craniotomy with biopsy 
was performed during  hospitalization.  Prior to the biopsy, her sodium 
was normal (140 mmol/L). Post-operatively, while in the recovery 
room, the patient was noted to have greater than 800 ml of urine output 
over the course of three hours. Overnight, the patient developed 
respiratory failure and was intubated. In the interim she had a urine 
output of approximately nine liters over a 12 hour period, and as a 
result, her serum sodium increased to 166 mmol/L. Endocrinology was 
then consulted to manage her DI. Patient was initially treated with 
DDAVP 1 mcg subcutaneously every eight hours with resultant 
improvement in her polyuria.  Fluids were replaced first with a 
combination of quarter Normal Saline and Half Normal Saline with 
free water via naso-gastric feeding tube and later with Half-normal 
saline only. Her serum Sodium normalized (145 mmol/L) in 48 hours. 
The biopsy findings revealed LCH (see fig 2). Peri-operatively, she 
had received dexamethasone. Additional work up revealed 
panhypopituitarism (see table 1). Dose of levothyroxine was increased 
to 112 mcg (from 50 mcg pre-op) by mouth daily. Physiological 
hydrocortisone replacement was started at 20mg in the morning and 
10mg in the evening.  
 
Fig1. MRI of the brain showing the 
lobulated enhancing mass centered in the 
suprasellar location measuring 2.8 cm (AP) 
x 2.4 cm (Transverse) x 1.6 cm with 
hyperintensity on flare. 
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•Despite being symptomatic for years, the patient 
was diagnosed only after the suprasellar lesion 
exhibited mass effect, leading to further work up. 
By this time, she had lost both anterior and 
posterior pituitary function.  
•The mean time from symptomatic onset to 
diagnosis of DI is 6.25 years and from DI to 
anterior pituitary involvement  is 5 years. 
•MRI guided biopsy is needed for definitive 
diagnosis. 
•Chemotherapy decreases the size of tumor, but 
does not   necessarily reverses DI. 
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Fig 2. A) A biopsy from the suprasellar mass contained patchy areas of a cellular lymphohistiocytic infiltrate, including 
scattered Langerhans cells with typical C-shaped nuclei (lower right, insert; hematoxylin and eosin, original 
magnification x200) along with a few small CD20 positive lymphocytes among the numerous T-cells (not pictured). B. 
Numerous Langerhans cells were also confirmed immunohistochemically (anti-CD1a, original magnification x200).  
Table 1: Post-op pituitary 
hormonal work up revealing 
panhypopituitarism.  
   CONCLUSION 
 
•Delay in diagnosing LCH as a cause of DI is in part 
due to very low incidence of LCH, particularly in 
adults.  
•This case highlights the importance of including 
LCH as the etiology of  DI.  
•An increased awareness could lead to possible early 
diagnosis and treatment. 
•High index of suspicion, early diagnosis, and 
treatment of LCH in cases of central DI in adults 
may prevent development of panhypopituitarism 
 
 
  
 
 
 
                          DISCUSSION 
 
•LCH is rare in adults and most often presents with 
symptoms related to bone, lung and skin.  
•Our case is unique as her symptoms are related only to 
pituitary involvement.  
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